NovaLaka

Company Overview

Snapshot

Founded in October 2015 by Eva Smagacz, NovaLaka operates with 1–10 employees. The company has secured $57K across one funding round from one investor. In June 2017, NovaLaka won first prize at the Global Pitch of China.

Business overview

NovaLaka is a Health Tech & Life Sciences company specializing in the development of slow-release transmucosal drug delivery systems. The company's core technology involves a polymeric composition designed to gradually release medication directly to mucosal tissues, such as those in the eyes. This polymeric film can serve as a vehicle for various active ingredients, ensuring controlled and effective delivery. NovaLaka primarily focuses on women's healthcare applications and operates within the Pharmaceuticals sector, serving markets like China.

Strategic signal

In June 2017, NovaLaka secured first prize at the Global Pitch of China, a significant validation of its drug delivery technology. This achievement highlights the company's potential for international market penetration and signals strong early recognition for its innovative approach to transmucosal drug delivery systems.

Company Intelligence Q&A

What is NovaLaka's primary focus?

NovaLaka develops slow-release transmucosal drug delivery systems, with a specialization in women's healthcare applications.

When was NovaLaka founded?

NovaLaka was founded in October 2015.

What is NovaLaka's core technology?

NovaLaka's core technology is a polymeric composition that serves as a drug-delivery system for mucosal tissue, designed to gradually release medication directly to the treatment area.

What significant award did NovaLaka receive?

In June 2017, NovaLaka won the first prize at the Global Pitch of China.

What is the company's current operational status?

NovaLaka is Non Active, having ceased to operate in December 2019.